|
|||||
|
|
In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme |
|
| Authors: | S-S Jean P-R Hsueh W-S Lee H-T Chang M-Y Chou I-S Chen J-H Wang C-F Lin J-M Shyr W-C Ko J-J Wu Y-C Liu W-K Huang L-J Teng C-Y Liu |
| Institution: | 1. Departments of Intensive Care Units and Internal Medicine, Min-Sheng General Hospital, Taoyuan County, Taiwan 2. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University Medical College, 7 Chung-Shan South Road, 100, Taipei, Taiwan 3. Department of Internal Medicine, Taipei Municipal WanFang Hospital, Taipei, Taiwan 4. Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei County, Taiwan 5. Department of Internal Medicine, Cheng Hsin Rehabilitation Medical Center, Taipei, Taiwan 6. Department of Internal Medicine, Cardinal Tien Hospital, Taipei County, Taiwan 7. Department of Internal Medicine, China Medical College Hospital, Taichung, Taiwan 8. Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 9. Department of Clinical Pathology, Taichung Veterans General Hospital, Taichung, Taiwan 10. Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan 11. School of Medical Technology, National Cheng-Kung University College of Medicine, Tainan, Taiwan 12. Department of Clinical Pathology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan 13. Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan 14. School of Medical Technology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan 15. Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan |
| Abstract: | This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC90 against ESBL-producing K. pneumoniae isolates was 2 µg/ml. Besides, doripenem with the MIC90 of 0.5 µg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |